A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
R-Pharm
Seagen Inc.
Pfizer
Eli Lilly and Company
AstraZeneca
Pfizer
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
AbbVie
Takeda
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Parabilis Medicines, Inc.
Genmab
Seagen Inc.
Coherus Oncology, Inc.
Summit Therapeutics
Novartis
Ono Pharmaceutical Co., Ltd.
AstraZeneca
EMD Serono
Multitude Therapeutics Inc.
Pfizer
Akeso
Seagen Inc.
AstraZeneca
Luye Pharma Group Ltd.
Bold Therapeutics, Inc.
Merck Sharp & Dohme LLC
GlaxoSmithKline
Tyligand Pharmaceuticals (Suzhou) Limited
Enliven Therapeutics
Akeso
Bristol-Myers Squibb
Bristol-Myers Squibb
BeiGene
Jazz Pharmaceuticals
Pfizer
Incyte Corporation
Toray Industries, Inc
Gilead Sciences
DEKA Biosciences
Taizhou Mabtech Pharmaceutical Co.,Ltd
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pierre Fabre Medicament
Hansoh BioMedical R&D Company
IGM Biosciences, Inc.
ImmunityBio, Inc.